INJ slides more than 10% as heavy selling hits despite ETF proposals and solid protocol metrics
Injective (INJ) fell 10.17% today as heavy intraday selling pressure outweighed recent positive protocol and governance developments. The decline is reinforced by the asset testing the lower end of a near-term support zone between $7.7 and $7.92, even as the overall technical structure remains bullish above major moving averages.
Highlights
- Injective generated $3.58 million in annual protocol revenue and advanced a governance proposal to preset core exchange gas costs.
- Multiple U.S. ETF applications featuring INJ, some with staking features, were submitted by 21Shares, Canary Capital, and REX-Osprey, but none represent direct ETF approval.
- INJ/USD trades between $7.7 and $7.92 under short-term selling pressure, with a projected five-day range of $6.61 to $9.49 and overbought momentum signals present.
Protocol revenue and ETF filings weigh against broad market selling
Injective reported annual protocol revenue of $3.58 million and introduced governance proposal IIP-709 to preset gas costs for core exchange messages. Multiple U.S. ETF proposals involving INJ were filed by firms including 21Shares, Canary Capital, and REX-Osprey, with some including staking strategies, though none signify direct ETF approval. Proof-of-stake issuance and continued buyback and burn mechanisms were also noted, accompanied by ongoing compliance and governance activities, though price action has remained under broader selling pressure.
Divergent technical signals as bullish structure meets overbought risk
INJ/USD is trading above its 20-day ($7.7), 50-day ($6.83), and 200-day ($5.15) moving averages, reflecting a bullish structure across all timeframes. The pair is currently positioned between the near-term floor at $7.7 and resistance at the Ichimoku Kijun level of $7.92, with both medium- and long-term alignment remaining bullish. Momentum indicators are mixed; MACD and ADX forecast further upside, and RSI at 61.36 is also in buy territory. However, CCI and Bull/Bear Power both signal overbought conditions, with BBP at 1.03 showing buyers dominate intraday action. Awesome Oscillator remains positive, Stochastic RSI reads neutral, and the Hull Moving Average has a sell forecast, highlighting signal divergence. After a downside gap of about 1%, INJ/USD trades near session lows at $7.82, with volatility at 9.23%, reflecting heavy intraday selling against broader positive momentum.
Earlier, analysts noted that Injective's bullish momentum was underpinned by strong technical alignment and increasing institutional engagement. The current article adds that despite today’s selloff and short-term support tests, INJ continues to exhibit robust technical structure, with the key level to watch being a potential breakout above $7.92 for renewed upside.